featured
Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
ESMO Open 2022 Nov 07;7(6)100601, M Schmidt, K Lübbe, T Decker, M Thill, L Bauer, V Müller, T Link, J Furlanetto, M Reinisch, C Mundhenke, O Hoffmann, MO Zahn, L Müller, C Denkert, M van Mackelenbergh, PA Fasching, N Burchardi, V Nekljudova, S LoiblFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.